Related Experiment Video
Updated: May 13, 2026
14:23
A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses
Published on: August 31, 2014
HIV-2 susceptibility to entry inhibitors
1Centre for Molecular Pathogenesis, Retrovirus and Associated Infections Unit (URIA-CPM), Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal.
AIDS Reviews
|March 2, 2013
Summary
Entry inhibitors show promise for treating Human Immunodeficiency Virus type 2 (HIV-2) infection. However, differences in viral envelope glycoproteins between HIV-1 and HIV-2 may impact treatment effectiveness.
Area of Science:
- Virology
- Immunology
- Pharmacology
Background:
- Limited therapeutic options are currently available for Human Immunodeficiency Virus type 2 (HIV-2) infections.
- Existing antiviral drugs often show reduced activity against HIV-2 compared to HIV-1.
- Entry inhibitors are being investigated as a potential treatment strategy for HIV-2.
Purpose of the Study:
- To review the susceptibility of HIV-2 to entry inhibitors.
- To examine the role of envelope glycoprotein evolution in HIV-2 response to entry inhibitors.
- To assess the potential of entry inhibitors to expand the therapeutic options for HIV-2.
Main Methods:
- Review of current scientific literature on HIV-2 susceptibility to entry inhibitors.
- Analysis of data on the evolution of HIV-1 and HIV-2 envelope glycoproteins.
- Examination of the sequence, structure, and function of viral envelope glycoproteins during infection.
Main Results:
- Maraviroc and other experimental entry inhibitors (CCR5 and CXCR4 antagonists) demonstrate inhibitory activity against primary HIV-2 isolates.
- These entry inhibitors also inhibit HIV-1, suggesting a potential for expanded therapeutic use.
- Significant differences exist in the evolutionary pathways of HIV-1 and HIV-2 envelope glycoproteins.
Conclusions:
- Entry inhibitors, including maraviroc, represent a promising avenue for HIV-2 treatment.
- Understanding the distinct evolution of HIV-2 envelope glycoproteins is crucial for predicting treatment response.
- Further research into entry inhibitor efficacy in the context of HIV-2 evolution is warranted.
Related Concept Videos
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:26Size and Structure of Viral Genomes
Viral genomes exhibit remarkable diversity in size, structure, and composition, influencing their replication strategies and interactions with host cells. These genomes consist of either DNA or RNA and may be linear or circular. Additionally, they can be single-stranded or double-stranded, with each configuration affecting how the virus propagates within a host. RNA viruses, for instance, generally have smaller genomes than DNA viruses, a factor that contributes to their high mutation rates and...